Proactive Investors - GSK (LON:GSK) PLC has announced the sale of 385.32 million ordinary shares in Haleon PLC (LON:HLN) at 324p per share, raising approximately £1.25 billion.
With this sale, GSK has fully exited its stake in the Sensodyne and Panadol maker and no longer holds any ordinary shares in Haleon.
Haleon was established in 2022 as a corporate spin-off from GSK.
Following the demerger and premium listing of Haleon on 18 July 2022, GSK initially retained a 12.94% stake.
Through numerous disposals since (including today’s), GSK has rained approximately £3.9 billion.
Futures point to blue-chip losses
The FTSE 100 is expected to open nine points lower at 8,422 this Friday after closing a few points lower yesterday.
Sage Group (LON:SGE) and easyJet (LON:EZJ) were among the biggest fallers, along with a horde of companies going ex-dividend.
Today, eyes are trained on Land Securities Group PLC (LON:LAND)’s finals, with its disposals programme front and centre of investors’ minds.
There is little of note on the macroeconomic calendar, barring the latest inflation print and CPI data from the eurozone.
Across the Atlantic, the Dow Jones is bracing for a momentous session as it attempts to reclaim 40,000 after briefly touching the record level on Thursday.